
https://www.science.org/content/blog-post/not-enough-progress-against-cancer
# Not Enough Progress Against Cancer? (January 2011)

## 1. SUMMARY

The article criticizes the standard for cancer drug approval in the early 2010s, arguing that statistically significant but clinically marginal benefits were being accepted too readily. It cites a *Journal of the National Cancer Institute* paper that analyzed Phase III trials for metastatic solid tumors, finding cases where drugs showed statistically significant improvements but minimal real-world benefit—such as erlotinib for pancreatic cancer, which extended median survival by only 10 days despite meeting statistical significance (HR = 0.82, p = 0.038). The authors proposed raising approval standards from mere statistical significance to requiring a "minimum clinically important difference," suggesting improvements of less than 1 month in median survival should not generally be considered clinically meaningful unless accompanied by reduced toxicity.

The piece notes that drugs are designed to detect the minimum difference regulators will accept, leading to a proliferation of "add-a-month-maybe therapies" that strain healthcare resources (with a rough threshold of US $100,000 per year of life gained being economically sustainable). Some researchers countered that focusing on median responses ignores outlier effects where subsets of patients experience substantial benefits, though the article questions whether this justifies treating entire populations. The author speculates that meaningful progress will require combinations of therapies hitting multiple mechanisms simultaneously—most of which don't exist yet—and that current incremental approaches may not be the most efficient path forward, even if they sustain the pharmaceutical industry's development pipeline.

## 2. HISTORY

After the 2011 article, several developments reshaped cancer drug evaluation and approval standards. By 2012-2013, regulatory frameworks began evolving toward more refined benefit assessment. The FDA's Oncology Center of Excellence, established in 2017, increasingly emphasized not just statistical significance but also clinically meaningful endpoints and patient-reported outcomes.

The decade saw meaningful progress in specific areas that exceeded the "marginal benefit" threshold discussed in 2011:

**Immunotherapy Breakthroughs**: Notably, checkpoint inhibitors (anti-PD-1/PD-L1 and anti-CTLA-4 drugs like pembrolizumab, nivolumab) for melanoma, lung cancer, and other solid tumors demonstrated substantial improvements in overall survival—often extending life by years rather than weeks or months, sometimes with durable responses. However, these benefits remained limited to subsets of patients (typically 20-40% depending on cancer type and biomarker status).

**Targeted Therapies with Meaningful Impact**: Drugs like osimertinib for EGFR-mutant lung cancer, crizotinib for ALK-positive lung cancer, and venetoclax for certain leukemias showed significant survival benefits (median improvements of 6-18 months) in biomarker-defined populations. This supported the precision medicine approach of identifying likely responders upfront.

**Drug Approvals**: From 2011-2020, the FDA approved approximately 80 new cancer drugs, with many demonstrating traditional clinically meaningful benefits. However, analysis published in *JAMA Oncology* in 2018 found that among 93 cancer drugs approved 2010-2016, 44% showed improvements in both overall survival and quality of life, while others showed mixed patterns.

**Value Assessment Initiatives**: Organizations like ASCO developed value frameworks (2015-2016) that explicitly incorporated magnitude of benefit, toxicity, and cost into assessment. ICER (Institute for Clinical and Economic Review), founded earlier but gaining prominence post-2011, systematically evaluated drugs using cost-effectiveness thresholds.

**FDA's Flexible Approaches**: The FDA increasingly utilized accelerated approvals, breakthrough therapy designations, and other pathways that allowed faster access to drugs showing dramatic early responses, even while requiring confirmatory trials to demonstrate sustained benefit.

**Challenges That Persisted**: Expensive but modest-benefit drugs continued to enter the market. For example, many CDK4/6 inhibitors showed progression-free survival improvements but more variable overall survival gains in metastatic breast cancer, continuing debate about what constitutes meaningful benefit for patients and healthcare systems.

**Economic Pressures**: Post-2011, cancer drug prices continued rising dramatically, with many therapies costing $100,000-150,000+ per year of life gained, straining healthcare budgets and prompting cost-effectiveness debates globally.

## 3. PREDICTIONS

**Prediction: "My guess is that meaningful cancer success will come from combinations of therapies that we mostly don't even have yet. I think that we'll need to hit several different mechanisms at the same time"**
- **What actually happened**: This proved prescient in several respects. Combination immunotherapy (e.g., ipilimumab + nivolumab for melanoma) did emerge with substantially better responses than single agents. However, many combination approaches remained incremental rather than transformative. The broader vision of hitting multiple mechanisms simultaneously did occur through combination strategies, but "therapies we mostly don't even have yet" understated the existing drug arsenal's combinatory potential.

**Implicit prediction: Statistical significance alone would continue as the primary regulatory endpoint**
- **What actually happened**: Partially accurate but evolving. While statistical significance remained foundational, regulators increasingly required or strongly considered additional factors including magnitude of benefit, quality of life assessments, and patient-reported outcomes by the late 2010s. The FDA's accelerated approval pathway required confirmatory evidence of clinical benefit, not just statistical separation.

**Implicit prediction: Marginal therapies would continue dominating the oncology pipeline**
- **What actually happened**: Mixed results. While many drugs with modest single-agent benefits continued entering the market, particularly in heavily pretreated populations, the 2011-2020 period also saw breakthrough therapies with dramatic benefits in biomarker-selected patients. The definition of "marginal" proved highly context-dependent—an "add-a-month" drug for rare cancers or for patients with exhausted options sometimes represented valuable progress, while similar gains in healthier populations with many alternatives might not.

**Prediction: Much of the work would remain "one thing after another" with mechanistic rationales not living up to expectations**
- **What actually happened**: Accurate observation that persisted. Many rationally designed pathway inhibitors showed disappointing clinical efficacy despite strong mechanistic justification. However, the field made substantial progress in identifying predictive biomarkers that explained variable responses and guided patient selection—a significant step forward from indiscriminately treating whole populations.

**Implicit prediction: Clinical trial endpoints focused on median responses would miss outlier benefits**
- **What actually happened**: Ongoing issue. While the "outlier effect" concern remained valid (some patients experienced dramatic, durable benefits from drugs with otherwise modest median effects), the development of predictive biomarkers—PD-L1 expression, tumor mutational burden, microsatellite instability, and specific genetic alterations—increasingly helped identify these potential outlier populations before treatment, partially addressing the 2011 concern.

## 4. INTEREST 

Rating: **7/10**

This article identified a crucial tension in cancer drug development that remained highly relevant throughout the subsequent decade. The issues raised—balancing access to promising therapies against demands for meaningful clinical benefit, managing healthcare costs while encouraging innovation, and refining regulatory standards beyond mere statistical significance—continued shaping oncology policy, clinical practice, and pharmaceutical development through the 2010s and beyond. The piece correctly anticipated that combination approaches and better patient selection would prove most fruitful, while the questions it raised about marginal benefits in cancer therapy gained rather than lost importance with rising drug prices and precision medicine capabilities.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20110124-not-enough-progress-against-cancer.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_